Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Resources
  • Careers
  • Contact
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Resources
  • Careers
  • Contact

Press Release

Ashvattha Therapeutics Selected to Present Late-Breaking Poster Presentation on Use of Novel Hepatocyte Targeted Hydroxyl Dendrimer Therapeutic at The Liver Meeting 2020

April 26, 2021November 2, 2020 by ashvatthaadmin

Ashvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.

Categories Press Release

Ashvattha Therapeutics Announces Formation of Scientific Advisory Board

November 12, 2020October 29, 2020 by ashvatthaadmin

Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.

Categories Press Release

Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020

November 12, 2020October 27, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.

Categories Press Release

Ashvattha Therapeutics Presents Preclinical Data at the American Society of Nephrology (ASN) Virtual Kidney Week 2020

November 12, 2020October 22, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020.

Categories Press Release

Ashvattha Therapeutics Appoints Industry Veteran George G. Montgomery to its Board of Directors

November 12, 2020October 7, 2020 by ashvatthaadmin

Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors.

Categories Press Release Leave a comment

Ashvattha Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

November 12, 2020September 10, 2020 by ashvatthaadmin

Jeffrey Cleland, Ph.D., chairman, chief executive officer and president of Ashvattha Therapeutics, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020.

Categories Press Release Leave a comment

Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19

November 12, 2020August 31, 2020 by ashvatthaadmin

Orpheris, a subsidiary of Ashvattha, announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe COVID-19.

Categories Press Release Leave a comment

Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation

November 12, 2020June 10, 2020 by ashvatthaadmin

Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers.

Categories Press Release Leave a comment

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients

November 12, 2020May 28, 2020 by ashvatthaadmin

Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of OP-101 in patients with severe COVID-19

Categories Press Release Leave a comment

Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting

November 12, 2020May 18, 2020 by ashvatthaadmin

Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June, 2020.

Categories Press Release Leave a comment
Older posts
Newer posts
← Previous Page1 Page2 Page3 Page4 Next →

Recent Posts

  • Ashvattha Therapeutics to Present at Upcoming Investor Conferences
  • Ashvattha Therapeutics to Present at Biotech Showcase 2023
  • Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer
  • Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress
  • Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

Recent Comments

    Archives

    • February 2023
    • January 2023
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2023 Ashvattha Therapeutics.
    • Privacy Policy
    © 2023 Ashvattha Therapeutics • Built with GeneratePress